In:
PLOS Pathogens, Public Library of Science (PLoS), Vol. 17, No. 10 ( 2021-10-7), p. e1009858-
Abstract:
Autoimmune diseases are often treated by glucocorticoids and immunosuppressive drugs that could increase the risk for infection, which in turn deteriorate disease and cause mortality. Low-dose IL-2 (Ld-IL2) therapy emerges as a new treatment for a wide range of autoimmune diseases. To examine its influence on infection, we retrospectively studied 665 patients with systemic lupus erythematosus (SLE) including about one third receiving Ld-IL2 therapy, where Ld-IL2 therapy was found beneficial in reducing the incidence of infections. In line with this clinical observation, IL-2 treatment accelerated viral clearance in mice infected with influenza A virus or lymphocytic choriomeningitis virus (LCMV). Noticeably, despite enhancing anti-viral immunity in LCMV infection, IL-2 treatment exacerbated CD8 + T cell-mediated immunopathology. In summary, Ld-IL2 therapy reduced the risk of infections in SLE patients and enhanced the control of viral infection, but caution should be taken to avoid potential CD8 + T cell-mediated immunopathology.
Type of Medium:
Online Resource
ISSN:
1553-7374
DOI:
10.1371/journal.ppat.1009858
DOI:
10.1371/journal.ppat.1009858.g001
DOI:
10.1371/journal.ppat.1009858.g002
DOI:
10.1371/journal.ppat.1009858.g003
DOI:
10.1371/journal.ppat.1009858.g004
DOI:
10.1371/journal.ppat.1009858.g005
DOI:
10.1371/journal.ppat.1009858.g006
DOI:
10.1371/journal.ppat.1009858.t001
DOI:
10.1371/journal.ppat.1009858.t002
DOI:
10.1371/journal.ppat.1009858.t003
DOI:
10.1371/journal.ppat.1009858.s001
DOI:
10.1371/journal.ppat.1009858.s002
DOI:
10.1371/journal.ppat.1009858.s003
DOI:
10.1371/journal.ppat.1009858.s004
DOI:
10.1371/journal.ppat.1009858.s005
DOI:
10.1371/journal.ppat.1009858.s006
DOI:
10.1371/journal.ppat.1009858.s007
Language:
English
Publisher:
Public Library of Science (PLoS)
Publication Date:
2021
detail.hit.zdb_id:
2205412-1
Bookmarklink